Lupin is currently trading at RS. 2041.40, up by 6.10 points or 0.30% from its previous closing of RS. 2035.30 on the BSE.

The stock opened at RS. 2044.95 and recorded a high of RS. 2046.50 and a low of RS. 2025.10. A total of 2047 shares have been traded so far.

Lupin, a BSE group 'A' stock with a face value of RS. 2, reached a 52-week high of RS. 2403.45 on January 2, 2025, and a 52-week low of RS. 1493.75 on June 4, 2024. Over the last week, the stock's high and low were RS. 2046.50 and RS. 1950.85, respectively. The company's current market capitalization stands at RS. 93431.10 crore.

The company's shareholding structure includes 46.95% held by promoters, 46.79% by institutions, and 6.26% by non-institutions.

In a strategic move, Lupin has incorporated a wholly-owned subsidiary named ‘Lupinlife Consumer Healthcare’. The company received its certificate of incorporation from the Ministry of Corporate Affairs on March 18, 2025.

Previously, Lupin secured tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg.

Lupin is a global pharmaceutical company focused on innovation, developing and marketing a broad range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).